<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513147</url>
  </required_header>
  <id_info>
    <org_study_id>INDOOR</org_study_id>
    <nct_id>NCT02513147</nct_id>
  </id_info>
  <brief_title>HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen</brief_title>
  <official_title>HIV Reservoir Dynamics After Switching to Dolutegravir in Patients With Two NRTI and a Protease Inhibitor Based Regimen. A Phase IV Open Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IrsiCaixa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess changes in viral reservoir after changing IP/r to&#xD;
      dolutegravir in HIV-1 infected patients maintaining undetectable viral load on Antiretroviral&#xD;
      Therapy (ART).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in mean of Long Terminal repeat (2LTR) in lymphocytes T Cluster of Differentiation 4+ (CD4 +) in peripheral blood obtained at week 1 of the study compared to day 0</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in mean of Long Terminal repeat (2LTR) in lymphocytes T Cluster of Differentiation 4+ (CD4 +) in peripheral blood obtained at week 2 of the study compared to day 0</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in mean of Long Terminal repeat (2LTR) in lymphocytes T Cluster of Differentiation 4+ (CD4 +) in peripheral blood obtained at week 4 of the study compared to day 0</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in mean of Long Terminal repeat (2LTR) in lymphocytes T Cluster of Differentiation 4+ (CD4 +) in peripheral blood obtained at week 12 of the study compared to day 0</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in mean of Long Terminal repeat (2LTR) in lymphocytes T Cluster of Differentiation 4+ (CD4 +) in peripheral blood obtained at week 24 of the study compared to day 0</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>2 NRTI+ Dolutegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>22 patients will be treated with 2 NRTI+Dolutegravir 50 mg during 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 NRTI + PI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>22 patients will be treated with 2 NRTI + PI during 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <arm_group_label>2 NRTI+ Dolutegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PI</intervention_name>
    <description>(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine</description>
    <arm_group_label>2 NRTI + PI</arm_group_label>
    <other_name>Fosamprenavir, atazanavir, lopinavir or darunavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 NRTI</intervention_name>
    <arm_group_label>2 NRTI+ Dolutegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 NRTI</intervention_name>
    <arm_group_label>2 NRTI + PI</arm_group_label>
    <other_name>2NRTI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients infected with HIV-1&#xD;
&#xD;
          -  HIV RNA &lt;50 copies / mL for ≥ 1 year with stable ART regimen (≥ 3 months) based on 2&#xD;
             NRTI and PI (Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of&#xD;
             ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir, if the 2 NRTIs are&#xD;
             abacavir + Lamivudine&#xD;
&#xD;
          -  CD4 + lymphocytes &gt; 200 / mm3&#xD;
&#xD;
          -  Signature of voluntary informed consent&#xD;
&#xD;
          -  A woman may be eligible to enter and participate in the study if:&#xD;
&#xD;
               1. No reproductive potential-defined as post-menopausal (12 months of spontaneous&#xD;
                  amenorrhea and ≥ 45 years of age) or physically incapable of getting pregnant&#xD;
                  with documented tubal ligation, hysterectomy or bilateral oophorectomy.&#xD;
&#xD;
               2. It is in childbearing age with a negative pregnancy test on the day of screening&#xD;
                  and on Day 1 and agrees to use one of the following contraceptive methods to&#xD;
                  prevent pregnancy:&#xD;
&#xD;
                    -  Complete abstinence from penis-vaginal from 2 weeks prior to administration&#xD;
                       of investigational product, throughout the study, and for at least 2 weeks&#xD;
                       after discontinuation of all study drugs;&#xD;
&#xD;
                    -  Double barrier method (male / spermicidal condom, male condom / diaphragm,&#xD;
                       diaphragm / spermicide);&#xD;
&#xD;
                    -  Any intrauterine device (IUD) with published data showing that the expected&#xD;
                       failure rate is &lt;1% per year (not all IUDs meet this criterion)&#xD;
&#xD;
                    -  Male sterilization confirmed before the entry of the female subject in the&#xD;
                       study, and that this man is the only sexual partner for women&#xD;
&#xD;
                    -  Approved hormonal contraception&#xD;
&#xD;
                    -  Any other method with published data show that the expected failure rate is&#xD;
                       &lt;1% per year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior virologic failure with an integrase inhibitor&#xD;
&#xD;
          -  Acquired Immune Deficiency Syndrome (AIDS)-defining illness in the last 48 weeks&#xD;
&#xD;
          -  Glomerular filtration rate &lt;50 mL / min, estimated by Chronic Kidney Disease&#xD;
             Epidemiology (CKD-EPI) formula&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) ≥5 times the Upper Limit Normal (ULN) or ALT ≥3 X ULN&#xD;
             and total bilirubin ≥1,5 ULN (with&gt; 35% direct bilirubin) and / or unstable liver&#xD;
             disease (with the presence of ascites, hepatic encephalopathy, hypoalbuminemia,&#xD;
             esophageal varices or persistent jaundice) or known biliary disorders excluded Gilbert&#xD;
             syndrome or asymptomatic lithiasis) .&#xD;
&#xD;
          -  Positive for hepatitis B (HBsAg +) or need for Hepatitis C Virus (HCV) treatment&#xD;
             during the study .&#xD;
&#xD;
          -  Subjects with severe hepatic impairment (Child Pugh Class C).&#xD;
&#xD;
          -  Patients unable to understand the study protocol or any other condition that in the&#xD;
             investigator's opinion could jeopardize compliance with the protocol&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  History or presence of allergy to any of the study drugs or their components&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

